Literature DB >> 20696776

CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis.

Steven Maltby1, Carolin Wohlfarth, Matthew Gold, Lori Zbytnuik, Michael R Hughes, Kelly M McNagny.   

Abstract

Eosinophil migration into the gut and the release of granular mediators plays a critical role in the pathogenesis of inflammatory bowel diseases, including ulcerative colitis. We recently demonstrated that eosinophil migration into the lung requires cell surface expression of the sialomucin CD34 on mast cells and eosinophils in an asthma model. Based on these findings, we investigated a similar role for CD34 in the migration of eosinophils and other inflammatory cells into the colon as well as explored the effects of CD34 ablation on disease development in a dextran sulfate sodium-induced model of ulcerative colitis. Our findings demonstrate decreased disease severity in dextran sulfate sodium-treated Cd34(-/-) mice, as assessed by weight loss, diarrhea, bleeding, colon shortening and tissue pathology, compared with wild-type controls. CD34 was predominantly expressed on eosinophils within inflamed colon tissues, and Cd34(-/-) animals exhibited drastically reduced colon eosinophil infiltration. Using chimeric animals, we demonstrated that decreased disease pathology resulted from loss of CD34 from bone marrow-derived cells and that eosinophilia in Cd34(-/-)IL5(Tg) animals was sufficient to overcome protection from disease. In addition, we demonstrated a decrease in peripheral blood eosinophil numbers following dextran sulfate sodium treatment. These findings demonstrate that CD34 was expressed on colon-infiltrating eosinophils and played a role in eosinophil migration. Further, our findings suggest CD34 is required for efficient eosinophil migration, but not proliferation or expansion, in the development of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696776      PMCID: PMC2928958          DOI: 10.2353/ajpath.2010.100191

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease.

Authors:  S C Bischoff; J Mayer; Q T Nguyen; M Stolte; M P Manns
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

2.  Binding of L-selectin to the vascular sialomucin CD34.

Authors:  S Baumheter; M S Singer; W Henzel; S Hemmerich; M Renz; S D Rosen; L A Lasky
Journal:  Science       Date:  1993-10-15       Impact factor: 47.728

3.  Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies.

Authors:  N A Lee; M P McGarry; K A Larson; M A Horton; A B Kristensen; J J Lee
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

4.  CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein.

Authors:  A Suzuki; D P Andrew; J A Gonzalo; M Fukumoto; J Spellberg; M Hashiyama; H Takimoto; N Gerwin; I Webb; G Molineux; R Amakawa; Y Tada; A Wakeham; J Brown; I McNiece; K Ley; E C Butcher; T Suda; J C Gutierrez-Ramos; T W Mak
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

5.  Activation of eosinophils in the pathophysiology of ulcerative colitis.

Authors:  K Makiyama; S Kanzaki; K Yamasaki; W Zea-Iriarte; Y Tsuji
Journal:  J Gastroenterol       Date:  1995-11       Impact factor: 7.527

6.  Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease.

Authors:  S C Bischoff; J Wedemeyer; A Herrmann; P N Meier; C Trautwein; Y Cetin; H Maschek; M Stolte; M Gebel; M P Manns
Journal:  Histopathology       Date:  1996-01       Impact factor: 5.087

7.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.

Authors:  M Kopf; F Brombacher; P D Hodgkin; A J Ramsay; E A Milbourne; W J Dai; K S Ovington; C A Behm; G Köhler; I G Young; K I Matthaei
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

8.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

Authors:  H M van Dullemen; S J van Deventer; D W Hommes; H A Bijl; J Jansen; G N Tytgat; J Woody
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

9.  Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin.

Authors:  S Baumhueter; N Dybdal; C Kyle; L A Lasky
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

10.  Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells.

Authors:  J R Beauchamp; L Heslop; D S Yu; S Tajbakhsh; R G Kelly; A Wernig; M E Buckingham; T A Partridge; P S Zammit
Journal:  J Cell Biol       Date:  2000-12-11       Impact factor: 10.539

View more
  19 in total

1.  Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11.

Authors:  Amanda Waddell; Richard Ahrens; Kris Steinbrecher; Burke Donovan; Marc E Rothenberg; Ariel Munitz; Simon P Hogan
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

2.  A familiar stranger: CD34 expression and putative functions in SVF cells of adipose tissue.

Authors:  Arnaud Scherberich; Nunzia Di Di Maggio; Kelly M McNagny
Journal:  World J Stem Cells       Date:  2013-01-26       Impact factor: 5.326

Review 3.  In situ hematopoiesis: a regulator of TH2 cytokine-mediated immunity and inflammation at mucosal surfaces.

Authors:  C C K Hui; K M McNagny; J A Denburg; M C Siracusa
Journal:  Mucosal Immunol       Date:  2015-03-18       Impact factor: 7.313

4.  CD34 is required for dendritic cell trafficking and pathology in murine hypersensitivity pneumonitis.

Authors:  Marie-Renée Blanchet; Jami L Bennett; Matthew J Gold; Elena Levantini; Daniel G Tenen; Melissa Girard; Yvon Cormier; Kelly M McNagny
Journal:  Am J Respir Crit Care Med       Date:  2011-06-03       Impact factor: 21.405

5.  CD34 promotes satellite cell motility and entry into proliferation to facilitate efficient skeletal muscle regeneration.

Authors:  Leslie Ann So Alfaro; Sarah A Dick; Ashley L Siegel; Adam S Anonuevo; Kelly M McNagny; Lynn A Megeney; D D W Cornelison; Fabio M V Rossi
Journal:  Stem Cells       Date:  2011-12       Impact factor: 6.277

Review 6.  Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections.

Authors:  Pooja Mehta; Glenn T Furuta
Journal:  Immunol Allergy Clin North Am       Date:  2015-06-17       Impact factor: 3.479

7.  Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.

Authors:  Yan Sun; Lian-Jie Lin; Yan Lin; Li-Xuan Sang; Min Jiang; Chang-Qing Zheng
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  IL-7Rα and L-selectin, but not CD103 or CD34, are required for murine peanut-induced anaphylaxis.

Authors:  Steven Maltby; Erin J DeBruin; Jami Bennett; Matthew J Gold; Matthew C Tunis; Zhiqi Jian; Jean S Marshall; Kelly M McNagny
Journal:  Allergy Asthma Clin Immunol       Date:  2012-08-31       Impact factor: 3.406

9.  Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage immune cell infiltration.

Authors:  Steven Maltby; Spencer Freeman; Matthew J Gold; Jennifer H E Baker; Andrew I Minchinton; Michael R Gold; Calvin D Roskelley; Kelly M McNagny
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

10.  Requirement for core 2 O-glycans for optimal resistance to helminth infection.

Authors:  Sarah C Mullaly; Menno J Oudhoff; Paul H Min; Kyle Burrows; Frann Antignano; David G Rattray; Alistair Chenery; Kelly M McNagny; Hermann J Ziltener; Colby Zaph
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.